Amneal Pharmaceuticals Acquires Kashiv BioSciences
Analysis based on 7 articles · First reported Apr 22, 2026 · Last updated Apr 23, 2026
The acquisition of Kashiv BioSciences by Amneal Pharmaceuticals is expected to create a fully integrated global biosimilars platform, potentially leading to increased competition and more affordable medicines in the U.S. market. This could drive accelerated growth for Amneal Pharmaceuticals and create long-term value for its shareholders.
Kashiv BioSciences has entered into a definitive agreement to be acquired by Amneal Pharmaceuticals, Inc. The transaction, expected to close in the second half of 2026, is subject to approval by Amneal Pharmaceuticals shareholders and regulatory bodies. This acquisition aims to combine Kashiv BioSciences' expertise in biosimilar development and manufacturing with Amneal Pharmaceuticals' commercial strengths, establishing a fully integrated global biosimilar platform. The companies anticipate this will accelerate their biosimilar pipeline, strengthen their U.S. commercial position for affordable medicines, and expand patient access to high-quality, affordable biologic medicines. Sandeep Athalye, CEO of Kashiv BioSciences, and Chirag Patel and Chintu Patel, Co-Founders and Co-CEOs of Amneal Pharmaceuticals, all expressed optimism about the strategic benefits and growth opportunities presented by this combination.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard